Fascin as a Useful Marker for Identifying Neural Components in Immature Teratomas of Human Ovary and Those Derived From Murine Embryonic Stem Cells

International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
Ryunosuke UmeharaMasahiko Kuroda

Abstract

Immature teratoma of the human ovary is a rare disease, and its diagnosis and grading are currently based on histologic evaluation of the presence and amount of immature neural components in the tumor. Despite the importance of tumor grading, immature neural components especially without rosette formation are difficult to identify, partly because useful biomarkers for them are not yet available. Toward this goal, we investigated 16 immature teratomas from human ovaries as well as 10 of those derived from murine embryonic stem cells transplanted into immunodeficient mice. Immunohistochemistry was performed for cytokeratin, glial fibrillary acidic protein, S100, and fascin. It was demonstrated that glial fibrillary acidic protein and S100 expression was not observed in the immature neural components of immature teratomas derived from both human ovary and embryonic stem cells, although their expression was detected in mature neural tissues. In contrast, fascin immunopositivity was clearly found in both mature and immature neural components regardless of rosette formation in immature teratomas derived from both human ovary and embryonic stem cells. Assessment of immature neural components by fascin immunostaining yielded the same o...Continue Reading

References

Jun 1, 1990·Pathology, Research and Practice·P LahdenneM Miettinen
Jan 1, 1989·Acta Neuropathologica·T Sangruchi, R A Sobel
Jun 15, 1983·American Journal of Obstetrics and Gynecology·H GallionD F Powell
May 1, 1984·Experimental Cell Research·A M WobusJ Schöneich
Oct 1, 1994·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·D M O'Connor, H J Norris
May 2, 2006·Obstetrics and Gynecology·Harriet O SmithClifford R Qualls
Sep 23, 2006·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Lawrence M Roth, Aleksander Talerman
Nov 24, 2006·The American Journal of Surgical Pathology·Debra L ZyngerXiming J Yang
Apr 28, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Ji Hoon PhiKyu-Chang Wang
Nov 13, 2007·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Kah-Wai NganYi-Yueh Hsieh
Nov 14, 2007·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Fa-Ren ZhangEn-Min Li
Apr 28, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Anuradha GopalanSatish K Tickoo
Aug 18, 2010·Communicative & Integrative Biology·Laura M Machesky, Ang Li
Jan 7, 2011·World Journal of Pediatrics : WJP·Song GuMin-Zhi Yin
Mar 11, 2011·Nature Reviews. Cancer·Uri Ben-David, Nissim Benvenisty
Oct 16, 2016·Journal of Pathology and Translational Medicine·Yun ChaiKyu-Rae Kim
Dec 22, 2016·The International Journal of Developmental Biology·Ivan Damjanov, Peter W Andrews
Mar 21, 2017·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Masako Hongo-KohamaMasahiko Kuroda

❮ Previous
Next ❯

Citations

Aug 22, 2020·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Marjaneh FarazestanianSomayeh Moein Darbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.